Assessment of Anti-RANKL Antibody in Post-menopausal Women

Summary

This is a single-center, open-label, dose-escalating study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of single dose subcutaneous injection of a fully human monoclonal antibody of receptor activator for nuclear factor-κ B ligand (RNAKL) (code name: TK006) in postmenopausal women.

Timeline

Start

2017-08-07

Primary completion

2018-12-30

Completion

2018-12-30

Drugs

Indications